Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Inhibrx Inc.
INBX | US
75.27
USD-0.48
-0.63%
INBX | US
About Inhibrx Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
75.27
Open
75.75
High
77.06
Low
72.36
Inhibrx Inc. a clinical-stage biopharmaceutical company focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109 a tetravalent agonist of death receptor 5 which is in Phase 2 clinical trials to treat cancers such as chondrosarcoma mesothelioma and pancreatic adenocarcinoma; INBRX-105 a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101 an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106 a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio Inc. Bristol-Myers Squibb Company and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla California.
View LessINBX | US
Risk
92.9
Sharpe
4.41
Luna's Score
61/100
Recommendation
Hold
Luna says (INBX | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
120.0%1 month
92.9%3 months
72.3%6 months
162.9%Returns
Fundamental Ratios
PE
0.13
Fwd. PE
-
Price to book
1.07
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.01
Ent. to rev.
5.56
PEG
-
Other Fundamentals
EBITDA
-300.93M
MarketCap
1.09B
MarketCap(USD)
1.09B
Div. yield
-
Op. margin
-160.90K
Erngs. growth
-
Rev. growth
233.30
Ret. on equity
-2.03K
Short ratio
5.76
Short perc.
5.71
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
19.94
Range1M
19.94
Range3M
31.31
Volumes: Market Activity
Rel. volume
1.41
Price X volume
23.75M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.01 | - | Cheaper |
| Ent. to Revenue | 5.56 | - | Cheaper |
| PE Ratio | 0.13 | 41.03 | Cheaper |
| Price to Book | 1.07 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 72.27 | - | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.09B | - | Emerging |
